Under what conditions will the biotech sector as a whole return to the investor spotlight – regardless of when the corona pandemic is under control? Is a new wave of takeovers coming in 2022? Which new technologies and therapies are particularly exciting for BB Biotech? These and other questions are explored in an interview with Dr. Daniel Koller, Head of the Investment Team.

Biotech companies often specialize in rare disease treatments but, as a result of the pandemic, they have displayed a greater interest in applying their cutting-edge technologies to treat disease indications that are significantly more prevalent. Meanwhile chronic and serious diseases are attracting more investor attention again.

Taking environmental, social and governance (“ESG”) factors into consideration is an integral part of BB Biotech´s investment approach. The investment process evaluates ESG in the context of risk and opportunities as a core part of the due diligence procedure that underpins every investment decision. The most important ESG aspect of the medical development process is the potential positive impact novel therapeutics can have on society: the aspiration of the biotech companies in which we invest is to develop drugs that address unmet medical needs.